テルイ　ヤスヒト   TERUI Yasuhito   照井　康仁    所属   埼玉医科大学  医学部 血液内科    職種   教授
論文種別	学術雑誌(原著)
言語種別	英語
査読の有無	査読あり
表題	Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma
掲載誌名	正式名：Jpn J Clin Oncol ISSNコード：14653621
掲載区分	国外
巻・号・頁	50,1265-1273頁
著者・共著者	Maruyama, D., Terui, Y., Yamamoto, K., Fukuhara, N., Choi, I., Kuroda, J., Ando, K., Hattori, A., Tobinai, K.
発行年月	2020
概要	In Japanese patients with relapsed or refractory classical Hodgkin lymphoma.|Japanese patients with previously treated classical Hodgkin lymphoma (aged ≥ 20 years) were administered nivolumab (3 mg/kg on Day 1 of 14-day cycles) until progressive disease, an unacceptable adverse event, or another clinically relevant reason.The centrally assessed overall response rate in 16 classical Hodgkin lymphoma patients was 87.5% . The median duration of response and progression-free survival were 8.5 (2.4-12.6) and 11.7 (1.8-42.3) months, respectively. The 3-year overall survival rate was 80.4%. Nivolumab was continued beyond progressive disease in seven patients; six were alive at the data cut-off. Adverse drug reactions occurred in all 17 patients with grades 3-4 adverse drug reactions in eight patients and no grade 5 adverse drug reactions. Pulmonary toxicities occurred in five patients; four of these occurred ≥17 months after starting nivolumab.
DOI	10.1093/jjco/hyaa117
文献番号	32776097